Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pangaea OncologyXMAD:PANG 61 9-Day RSI is 60.85 as of Jul. 26, 2026. GuruFocus rates XMAD:PANG with a GF Score™ of 61/100 and a GF Value™ of €2.18 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 216 Medical Diagnostics & Research companies, Pangaea Oncology ranks worse than 83.8% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
As of today (2026-07-26), Pangaea Oncology's 9-Day RSI is 60.85.
The industry rank for Pangaea Oncology's 9-Day RSI or its related term are showing as below:
XMAD:PANG's 9-Day RSI is ranked worse than 83.8% of 216
companies
in the Medical Diagnostics & Research industry
Industry Median: 46.565
vs XMAD:PANG: 60.85
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Pangaea Oncology 9-Day RSI Related Terms
XMAD:PANG vs TMO, DHR, IDXX: 9-Day RSI Comparison
For the Diagnostics & Research subindustry, Pangaea Oncology's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pangaea Oncology 9-Day RSI vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Pangaea Oncology's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Pangaea Oncology's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pangaea Oncology (XMAD:PANG) has a 9-Day RSI of 60.85 as of Jul. 26, 2026. According to the industry distribution chart, Pangaea Oncology ranks #181 out of 216 companies in the Medical Diagnostics & Research industry, placing it in the top 83.8%.
Is Pangaea Oncology's 9-Day RSI too high?
Pangaea Oncology's current 9-Day RSI is 60.85. The Medical Diagnostics & Research industry median 9-Day RSI is 46.57. Pangaea Oncology's value of 60.85 is 30.7% above this industry median. Based on the distribution chart, Pangaea Oncology ranks #181 out of 216 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Pangaea Oncology has a GF Score™ of 61/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pangaea Oncology's 9-Day RSI compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Pangaea Oncology ranks #181 out of 216 companies for 9-Day RSI. This places Pangaea Oncology in the lower half of its industry. The industry median 9-Day RSI is 46.57. Pangaea Oncology's value of 60.85 is 30.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Medical Diagnostics & Research company?
The median 9-Day RSI among Medical Diagnostics & Research companies is 46.57, based on 216 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pangaea Oncology's current 9-Day RSI of 60.85 is 30.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median 9-Day RSI is 46.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pangaea Oncology's current 9-Day RSI is 60.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pangaea Oncology stock overvalued right now?
Based on GuruFocus' analysis, Pangaea Oncology (XMAD:PANG) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.18, compared to a current price of €1.55 — trading 28.9% below its estimated fair value. The current 9-Day RSI is 60.85 and 30.7% above the Medical Diagnostics & Research industry median of 46.57. Pangaea Oncology's overall GF Score™ is 61/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Pangaea Oncology (XMAD:PANG), the current 9-Day RSI is 60.85 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pangaea Oncology (XMAD:PANG) Overvalued in 2026?
Based on GuruFocus' analysis, Pangaea Oncology stock appears to be undervalued.
The current stock price of €1.55 is trading 28.9% below its estimated GF Value™ of €2.18.
GuruFocus considers Pangaea Oncology to be Modestly Undervalued.
Key valuation signals for XMAD:PANG:
9-Day RSI: 60.85
GF Value™: €2.18 vs. price of €1.55 (28.9% below fair value)
Industry Position: 30.7% above the Medical Diagnostics & Research median (#181 of 216)
No single metric tells the full story. See the XMAD:PANG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pangaea Oncology SA is a medical services company. The company provides a wide range of services to cancer patients, as well as global pharmaceutical and biotech clients, in the fields of molecular diagnostics, clinical trials, in vitro drug profiling, dx platform validation, and biomarker discovery. The company has aggregated its operations into two segments, Clinical Care division and Diagnostic and Research and Development services division. Clinical Care division delivers medical oncology services and related activities. Diagnostic and Research and Development services division provides diagnostic and in-vitro services.
61GF Score
Get the complete analysis for XMAD:PANG
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:PANG has been successfully added to your 
